Mixed Infections Treatment Guidelines

Introduction to Mixed Infections

• When facing a mixed infection with organisms showing different susceptibility patterns to ciprofloxacin, using ciprofloxacin alone would be ineffective against the resistant organism, potentially leading to treatment failure and worse clinical outcomes, thus combination therapy with antibiotics that cover both organisms is recommended 1

Diagnosis and Treatment Approach

• Identify both pathogens through appropriate cultures before starting therapy when possible, and choose antibiotics with activity against both organisms based on susceptibility testing, considering the site of infection when selecting appropriate antimicrobial regimens 1
• The Infectious Diseases Society of America recommends using combination therapy that addresses both the ciprofloxacin-resistant and ciprofloxacin-sensitive organisms, with a first-line option of Cefepime (2g IV q12h) or meropenem (1g IV q8h) for broad coverage against most gram-negative pathogens including those resistant to ciprofloxacin 1
• For Pseudomonas aeruginosa infections, cefepime is particularly effective even against ciprofloxacin-resistant strains, according to the Clinical Infectious Diseases guidelines 1
• Another first-line option is combination therapy with a beta-lactam based on susceptibility (e.g., ampicillin-sulbactam, piperacillin-tazobactam) plus clindamycin (for gram-positive coverage) plus ciprofloxacin (for susceptible gram-negative organisms), as recommended by the Infectious Diseases Society of America 2
• For severe infections, consider carbapenems (imipenem, meropenem, or ertapenem) which provide broad coverage against both gram-positive and gram-negative organisms, according to the Clinical Infectious Diseases guidelines 2
• Ceftazidime-avibactam with metronidazole or tigecycline is also a first-line option, providing coverage against resistant gram-negative organisms and anaerobes, as recommended by the Journal of Microbiology, Immunology and Infection 3

Treatment Duration and Monitoring

• The duration of therapy typically ranges from 7-14 days depending on clinical response, but can be up to 4-6 weeks for prosthetic joint infections or bone/joint infections, and 5-14 days for complicated intra-abdominal infections based on source control and clinical improvement, according to the Clinical Infectious Diseases and Journal of Microbiology, Immunology and Infection guidelines 1, 3
• Assess clinical response within 48-72 hours of initiating therapy, and consider repeat cultures if no clinical improvement, while monitoring for drug toxicities, especially with combination regimens 1

Special Considerations

• For mixed infections involving Pseudomonas and other organisms, use cefepime (2g IV q12h) or meropenem (1g IV q8h), as recommended by the Clinical Infectious Diseases guidelines 1
• For necrotizing fasciitis with mixed flora, use ampicillin-sulbactam plus clindamycin plus ciprofloxacin, according to the Infectious Diseases Society of America guidelines 2
• For non-necrotizing infections, use an appropriate beta-lactam based on susceptibility patterns, as recommended by the Clinical Infectious Diseases guidelines 2